Carcinoma of unknown primary: Molecular tumor board-based therapy.
作者信息
Shreenivas Aditya V, Kato Shumei, Hu Jingjing, Skefos Catherine, Sicklick Jason, Kurzrock Razelle
机构信息
Division of Hematology and Medical Oncology, Medical College of Wisconsin Cancer Center, Milwaukee, Wisconsin, USA.
Medical Oncology, Department of Medicine, Moores Cancer Center, University of California-San Diego, San Diego, California, USA.
出版信息
CA Cancer J Clin. 2022 Nov;72(6):510-523. doi: 10.3322/caac.21748. Epub 2022 Aug 25.
Abstract
摘要
相似文献
1
Carcinoma of unknown primary: Molecular tumor board-based therapy.原发灶不明癌：基于分子肿瘤学专家组的治疗
CA Cancer J Clin. 2022 Nov;72(6):510-523. doi: 10.3322/caac.21748. Epub 2022 Aug 25.
2
Molecular diagnosis and site-specific therapy in cancer of unknown primary: an important milestone.未知原发癌的分子诊断与位点特异性治疗：一个重要的里程碑。
Lancet Oncol. 2024 Aug;25(8):955-956. doi: 10.1016/S1470-2045(24)00344-9. Epub 2024 Jul 25.
3
Evaluation of Carcinoma of Unknown Primary on Cytologic Specimens.细胞学标本中不明原发癌的评估
Surg Pathol Clin. 2018 Sep;11(3):545-562. doi: 10.1016/j.path.2018.04.006.
4
Cancer of Unknown Primary Site: New Treatment Paradigms in the Era of Precision Medicine.原发部位不明的癌症：精准医学时代的新治疗模式
Am Soc Clin Oncol Educ Book. 2018 May 23;38:20-25. doi: 10.1200/EDBK_100014.
5
Unknown primary squamous cell carcinoma of the head and neck: a review of diagnosis, treatment and outcomes.头颈部原发性不明的鳞状细胞癌：诊断、治疗及预后综述
Asian J Surg. 2002 Apr;25(2):188-93. doi: 10.1016/S1015-9584(09)60172-X.
6
Management of unknown primary tumor.未知原发肿瘤的管理
Head Neck. 2003 Jun;25(6):499-504. doi: 10.1002/hed.10287.
7
Tailoring therapy to hidden primary tumors.针对隐匿性原发性肿瘤定制治疗方案。
Cancer Discov. 2015 May;5(5):OF5. doi: 10.1158/2159-8290.CD-NB2015-036. Epub 2015 Mar 18.
8
Summary of the Standards, Options and Recommendations for the management of patients with carcinoma of unknown primary site (2002).不明原发部位癌患者管理的标准、选择及建议总结（2002年）
Br J Cancer. 2003 Aug;89 Suppl 1(Suppl 1):S59-66. doi: 10.1038/sj.bjc.6601085.
9
NCCN practice guidelines for occult primary tumors. National Comprehensive Cancer Network.NCCN隐匿性原发性肿瘤实践指南。美国国立综合癌症网络。
Oncology (Williston Park). 1998 Nov;12(11A):226-309.
10
A case of metastatic adenocarcinoma of unknown primary in a pediatric patient: Opportunities for precision medicine.一名儿科患者的原发性不明转移性腺癌病例：精准医学的机遇
Pediatr Blood Cancer. 2021 Apr;68(4):e28780. doi: 10.1002/pbc.28780. Epub 2020 Dec 12.
引用本文的文献
1
Advances in molecular pathology and therapy of non-small cell lung cancer.非小细胞肺癌分子病理学与治疗的进展
Signal Transduct Target Ther. 2025 Jun 15;10(1):186. doi: 10.1038/s41392-025-02243-6.
本文引用的文献
1
Incidence of FGFR2 Amplification and FGFR2 Fusion in Patients with Metastatic Cancer Using Clinical Sequencing.使用临床测序技术检测转移性癌症患者中FGFR2扩增和FGFR2融合的发生率。
J Oncol. 2022 Mar 18;2022:9714570. doi: 10.1155/2022/9714570. eCollection 2022.
2
Cholangiocarcinoma With Genetic Aberrations: A Unique Clinical Phenotype.伴有基因畸变的胆管癌：一种独特的临床表型。
JCO Precis Oncol. 2018 Nov;2:1-12. doi: 10.1200/PO.17.00080.
3
Therapeutic Actionability of Circulating Cell-Free DNA Alterations in Carcinoma of Unknown Primary.不明原发癌中循环游离 DNA 改变的治疗可操作性。
JCO Precis Oncol. 2021 Nov 3;5. doi: 10.1200/PO.21.00011. eCollection 2021.
4
Molecular profiling of advanced malignancies guides first-line N-of-1 treatments in the I-PREDICT treatment-naïve study.先进恶性肿瘤的分子谱分析指导 I-PREDICT 研究中一线 N-of-1 治疗。
Genome Med. 2021 Oct 4;13(1):155. doi: 10.1186/s13073-021-00969-w.
5
Appropriate PD-L1 Cutoff Value for Gastric Cancer Immunotherapy: A Systematic Review and Meta-Analysis.胃癌免疫治疗的合适程序性死亡受体 1 配体（PD-L1）临界值：一项系统评价与荟萃分析
Front Oncol. 2021 Sep 1;11:646355. doi: 10.3389/fonc.2021.646355. eCollection 2021.
6
Genome-wide Sequencing of Cell-free DNA Enables Detection of Copy-number Alterations in Patients with Cancer Where Tissue Biopsy is Not Feasible.游离 DNA 全基因组测序可检测组织活检不可行的癌症患者的拷贝数改变。
Mol Cancer Ther. 2021 Nov;20(11):2274-2279. doi: 10.1158/1535-7163.MCT-20-1066. Epub 2021 Aug 31.
7
Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study.英菲格拉替尼（BGJ398）治疗既往接受过治疗的伴有 FGFR2 融合或重排的局部晚期或转移性胆管癌患者：来自多中心、开放标签、单臂、2 期研究的成熟结果。
Lancet Gastroenterol Hepatol. 2021 Oct;6(10):803-815. doi: 10.1016/S2468-1253(21)00196-5. Epub 2021 Aug 3.
8
Identification of Targetable Gene Fusions and Structural Rearrangements to Foster Precision Medicine in Wild-Type Pancreatic Cancer.鉴定可靶向的基因融合和结构重排，以促进野生型胰腺癌的精准医疗。
JCO Precis Oncol. 2021 Jan 11;5. doi: 10.1200/PO.20.00265. eCollection 2021.
9
Molecular alterations in pancreatic tumors.胰腺肿瘤中的分子改变。
World J Gastroenterol. 2021 Jun 7;27(21):2710-2726. doi: 10.3748/wjg.v27.i21.2710.
10
A Challenging Task: Identifying Patients with Cancer of Unknown Primary (CUP) According to ESMO Guidelines: The CUPISCO Trial Experience.一项具有挑战性的任务：根据 ESMO 指南识别癌症未知原发灶（CUP）患者：CUPISCO 试验经验。
Oncologist. 2021 May;26(5):e769-e779. doi: 10.1002/onco.13744. Epub 2021 Mar 25.
Zotero 插件